Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38902935.
- Also identified by DOI 10.1093/cid/ciae332 and PMC identifier 12057557.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs 10%; P = .002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.
Medical subject headings
- Ceftazidime
- Cephalosporins
- Azabicyclo Compounds
- Pseudomonas aeruginosa
- Anti-Bacterial Agents
- Drug Resistance, Multiple, Bacterial
- Pseudomonas Infections
- Bacteremia
- Pneumonia, Bacterial
- Penicillanic Acid